NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical for Ophthalmic Quinolone Antibiotic

NTC has granted exclusive license and distribution rights to one of its research and development products, a fixed combination in eye drops, in Israel to Taro Pharmaceutical Industries. The product combines a quinolone antibiotic with an anti-inflammatory steroid in eye drops with the aim of providing an appropriate and rational treatment for post-cataract surgery.

Terms of the deal were not disclosed.

To provide supportive evidence to its product, NTC completed Leader7, an international, clinical study designed to compare a 1-week course of antibiotic prophylaxis to a 2-week course with a reference comparator, in the prevention and treatment of inflammation and prevention of infection associated with cataract surgery in adults.

“The ability to bring Italian innovation internationally thanks to partnerships with global leaders like Taro is a great achievement for NTC and it demonstrates our commitment to the ophthalmology arena, in which NTC is building a strong portfolio and a promising pipeline,” Riccardo Carbucicchio, Chairman and CEO of NTC, said in a company news release. “We are excited to have embraced this partnership in Israel for this asset with Taro and we hope that this is only the beginning of a long and successful collaboration.”

This novel NTC fixed combination product has been now partnered and out-licensed by NTC across 60 countries all over the world.